Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1976 Nov;39(11):1101–1108. doi: 10.1136/jnnp.39.11.1101

Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.

J D Parkes, A G Debono, C D Marsden
PMCID: PMC1083310  PMID: 1036999

Abstract

Thirty-seven patients with Parkinsonism were treated with bromocriptine 2.5-300 mg daily. Bromocriptine, alone or combined with levodopa, caused a 20-30% reduction in disability scores in 11 patients treated for one year. Tolerance did not develop during this period. Bromocriptine treatment was not of value in six patients who had previously not responded or who had lost their response to levodopa. However, in four of five patients with response swings on levodopa due to rapid changes in plasma dopa levels, the addition of bromocriptine caused a more stable response. Dose response curves to bromocriptine 12.5, 25, 50, and 100 mg and to levodopa 250, 500, 1000, and 2000 mg were studied in seven patients. Levodopa 2 g had a greater therapeutic effect and caused a greater rise in plasma growth hormone concentration than bromocriptine 100 mg. Levodopa caused emesis more commonly and hallucinations less commonly than bromocriptine. Bromocriptine appears to be a less potent stimulant than dopamine, and has both pre- and post-synaptic effects. Metoclopramide 60 mg oral was given 30 minutes before bromocriptine or levodopa to establish whether this caused dopamine-receptor blockade. Metoclopramide acted as a competitive antagonist to the anti-Parkinsonism and growth hormone effect of both drugs and in individual cases prevented emesis and hallucinations. The fall in blood pressure due to bromocriptine or levodopa was not antagonised by metoclopramide. Central and peripheral vascular dopamine receptors may be different in nature.

Full text

PDF
1101

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Camanni F., Massara F., Belforte L., Molinatti G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. J Clin Endocrinol Metab. 1975 Mar;40(3):363–366. doi: 10.1210/jcem-40-3-363. [DOI] [PubMed] [Google Scholar]
  3. Corrodi H., Farnebo L. O., Fuxe K., Hamberger B. Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Eur J Pharmacol. 1975 Feb;30(2):172–181. doi: 10.1016/0014-2999(75)90097-7. [DOI] [PubMed] [Google Scholar]
  4. Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973 May;25(5):409–412. doi: 10.1111/j.2042-7158.1973.tb10037.x. [DOI] [PubMed] [Google Scholar]
  5. Del Pozo E., Del Re R. B., Varga L., Friesen H. The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine). J Clin Endocrinol Metab. 1972 Nov;35(5):768–771. doi: 10.1210/jcem-35-5-768. [DOI] [PubMed] [Google Scholar]
  6. Fuxe K., Corrodi H., Hökfelt T., Lidbrink P., Ungerstedt U. Ergocornine and 2-Br-alpha-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med Biol. 1974 Apr;52(2):121–132. [PubMed] [Google Scholar]
  7. Johnson A. M., Loew D. M., Vigouret J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol. 1976 Jan;56(1):59–68. doi: 10.1111/j.1476-5381.1976.tb06959.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Marsden C. D., Barry P. E., Parkes J. D., Zilkha K. J. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10–14. doi: 10.1136/jnnp.36.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  10. McNay J. L., Goldberg L. I. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther. 1966 Jan;151(1):23–31. [PubMed] [Google Scholar]
  11. Miller R. Metoclopramide and dopamine receptor blockade. Neuropharmacology. 1976 Aug;15(8):463–469. doi: 10.1016/0028-3908(76)90056-3. [DOI] [PubMed] [Google Scholar]
  12. SCHALCH D. S., PARKER M. L. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. doi: 10.1038/2031141a0. [DOI] [PubMed] [Google Scholar]
  13. Setler P. E., Pendleton R. G., Finlay E. The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs. J Pharmacol Exp Ther. 1975 Mar;192(3):702–712. [PubMed] [Google Scholar]
  14. Takahara J., Arimura A., Schally A. V. Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology. 1974 Aug;95(2):462–465. doi: 10.1210/endo-95-2-462. [DOI] [PubMed] [Google Scholar]
  15. Thorner M. O. Dopamine is an important neurotransmitter in the autonomic nervous system. Lancet. 1975 Mar 22;1(7908):662–665. doi: 10.1016/s0140-6736(75)91762-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES